Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A multicenter, prospective, randomized, open label study to assess the effect of serelaxin versus standard of care in acute heart failure (AHF) patients

Trial Profile

A multicenter, prospective, randomized, open label study to assess the effect of serelaxin versus standard of care in acute heart failure (AHF) patients

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 02 Jul 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Serelaxin (Primary)
  • Indications Acute heart failure
  • Focus Registrational; Therapeutic Use
  • Acronyms RELAX AHF-Pan EU; RELAX-AHF-EU
  • Sponsors Novartis Pharma A.G.; Novartis Pharmaceuticals
  • Most Recent Events

    • 30 Jun 2019 Trial has been discontinued in UK, according to European Clinical Trials Database record.
    • 02 Jan 2019 Primary endpoint (Change from baseline in worsening HF (WHF) requiring rescue therapy or all cause death, through Day 5) has been met as per results published in the European Journal of Heart Failure
    • 02 Jan 2019 Results published in the European Journal of Heart Failure
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top